An evaluation of liposome-based diagnostics of pulmonary and extrapulmonary tuberculosis

Tandel, Nikunj; Joseph, Aviva; Joshi, Aishwarya; Shrama, Priya; Mishra, R. B.; Tyagi, Rajeev K.; Bisen, Prakash S.

doi:10.1080/14737159.2020.1740596

Cited by 7 publications

(8 citation statements)

References 50 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Lung-homing liposomes targeting Mtb lowers treatment duration and hepatotoxicity in pulmonary tuberculosis [40,52,53]. Swami et al recently showed that PLGA nanocarriers could be used for the targeted delivery of drugs to bone cancer [35].…”

Section: Discussionmentioning

confidence: 99%

Preclinical Evidence of Nanomedicine Formulation to Target Mycobacterium tuberculosis at Its Bone Marrow Niche

et al. 2020

View full text Add to dashboard Cite

One-third of the world’s population is estimated to be latently infected with Mycobacterium tuberculosis (Mtb). Recently, we found that dormant Mtb hides in bone marrow mesenchymal stem cells (BM-MSCs) post-chemotherapy in mice model and in clinical subjects. It is known that residual Mtb post-chemotherapy may be responsible for increased relapse rates. However, strategies for Mtb clearance post-chemotherapy are lacking. In this study, we engineered and formulated novel bone-homing PEGylated liposome nanoparticles (BTL-NPs) which actively targeted the bone microenvironment leading to Mtb clearance. Targeting of BM-resident Mtb was carried out through bone-homing liposomes tagged with alendronate (Ald). BTL characterization using TEM and DLS showed that the size of bone-homing isoniazid (INH) and rifampicin (RIF) BTLs were 100 ± 16.3 nm and 84 ± 18.4 nm, respectively, with the encapsulation efficiency of 69.5% ± 4.2% and 70.6% ± 4.7%. Further characterization of BTLs, displayed by sustained in vitro release patterns, increased in vivo tissue uptake and enhanced internalization of BTLs in RAW cells and CD271+BM-MSCs. The efficacy of isoniazid (INH)- and rifampicin (RIF)-loaded BTLs were shown using a mice model where the relapse rate of the tuberculosis was decreased significantly in targeted versus non-targeted groups. Our findings suggest that BTLs may play an important role in developing a clinical strategy for the clearance of dormant Mtb post-chemotherapy in BM cells.

show abstract

Section: Discussionmentioning

confidence: 99%

Preclinical Evidence of Nanomedicine Formulation to Target Mycobacterium tuberculosis at Its Bone Marrow Niche

et al. 2020

View full text Add to dashboard Cite

show abstract

“…D. Banghamam, a British hematologist, in 1961, are spherical microscopic aqueous vesicles surrounded by a lipid membrane(s) composed of natural phospholipids like phosphatidylcholine, serine, ethanolamine, and inositol. Due to their amphipathic nature, they can encapsulate lipophilic and hydrophilic drugs [39][40]. The liposome size is ~0.05 µm to 5 µm and can be synthesized in a desired shape, size, surface composition, and lamellar composition [40].…”

Section: Solid Lipid Nanoparticles (Slns)mentioning

confidence: 99%

Recent Advances in Nanocarrier Based Therapeutic and Diagnostic Approaches in Tuberculosis

Ahmad,

Pandey,

Singh

et al. 2023

Precision Nanomedicine

View full text Add to dashboard Cite

<img src=” https://s3.amazonaws.com/production.scholastica/article/90699/large/prnano_1072023gaf.jpg?1701882189”> Tuberculosis is the second most fatal infectious disease; each year, it causes millions of deaths worldwide. Although several anti-TB drugs are currently available, the problem with these drugs is that they require a prolonged duration of treatment, with high drug doses. In addition, patient non-adherence to therapy subsequently leads to the development of multidrug-resistant and ex-tensively drug-resistant tuberculosis. Therefore, we need to develop an effective and robust nano-carrier-based drug delivery system to overcome these issues and improve the therapeutic potential of drug dose/duration and patient compliance. This review article focuses on the cur-rently available various nanotechnology-based therapeutic approaches, including lipid nanopar-ticles, polymeric particles, carbon nanotubes, glucan, and alginate-based nano-carrier systems for effective anti-TB drug delivery to host macrophage for mycobacterium killing. Finally, we also present some promising recent nanotechnology-based mycobacterial detection systems us-ing silver nanoparticles, silica nanoparticles, magnetic nanoparticles, quantum dots, and magnet-ic barcode assay that have recently emerged as the latest diagnostic tool. Functionalized nano-materials for emerging Aggregation-induced photodynamic therapy as next-generation theranostics have also been discussed as a novel option for TB diagnosis and therapy.

show abstract

“…The reported liposomal carriers have shown effectiveness against multi-drug and extensively drug-resistant strains of Mycobacterium (Bekraki, 2020). Liposomes have also been a helpful system for vaccine delivery in managing tuberculosis (Tyagi et al, 2015;Tyagi et al, 2016;Diogo et al, 2019;Tandel et al, 2020;Chaudhari et al, 2021).…”

Section: Liposomesmentioning

confidence: 99%

Nanocarrier-Based Approaches for the Efficient Delivery of Anti-Tubercular Drugs and Vaccines for Management of Tuberculosis

2021

View full text Add to dashboard Cite

Drug-resistant species of tuberculosis (TB), which spread faster than traditiona TB, is a severely infectious disease. The conventional drug therapy used in the management of tuberculosis has several challenges linked with adverse effects. Hence, nanotherapeutics served as an emerging technique to overcome problems associated with current treatment. Nanotherapeutics helps to overcome toxicity and poor solubility issues of several drugs used in the management of tuberculosis. Due to their diameter and surface chemistry, nanocarriers encapsulated with antimicrobial drugs are readily taken up by macrophages. Macrophages play a crucial role as they serve as target sites for active and passive targeting for nanocarriers. The surface of the nanocarriers is coated with ligand-specific receptors, which further enhances drug concentration locally and indicates the therapeutic potential of nanocarriers. This review highlights tuberculosis’s current facts, figures, challenges associated with conventional treatment, different nanocarrier-based systems, and its application in vaccine development.

show abstract

An evaluation of liposome-based diagnostics of pulmonary and extrapulmonary tuberculosis

Cited by 7 publications

References 50 publications

Preclinical Evidence of Nanomedicine Formulation to Target Mycobacterium tuberculosis at Its Bone Marrow Niche

Preclinical Evidence of Nanomedicine Formulation to Target Mycobacterium tuberculosis at Its Bone Marrow Niche

Recent Advances in Nanocarrier Based Therapeutic and Diagnostic Approaches in Tuberculosis

Nanocarrier-Based Approaches for the Efficient Delivery of Anti-Tubercular Drugs and Vaccines for Management of Tuberculosis

Contact Info

Product

Resources

About